

## CURRICULUM VITAE

Revised: 19/JUL/2018

### Changhoon Yoo, M.D.

Assistant Professor,  
Department of Oncology, Asan Medical Center,  
University of Ulsan College of Medicine, Seoul, Korea

#### Address (Work)

Department of Oncology,  
Asan Medical Center, University of Ulsan College of Ulsan  
88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea  
Tel: 82-2-3010-1727  
Fax: 82-2-3010-6961  
E-mail: [yooc@amc.seoul.kr](mailto:yooc@amc.seoul.kr), [cyoo.amc@gmail.com](mailto:cyoo.amc@gmail.com)

#### Education

- |                   |  |
|-------------------|--|
| 2000. 3 – 2002. 2 | Pre-Medicine<br>University of Ulsan College of Medicine<br>Seoul, Korea  |
| 2002. 3 – 2006. 2 | M.D.<br>Graduate summa cum laude<br>University of Ulsan College of Medicine<br>Seoul, Korea  |
| 2005. 6 – 2005. 8 | Visiting medical student<br>Department of Oncology,<br>Mayo Clinic, Rochester, MN  |
| 2009. 3 – 2011.2  | Master of Science<br>Postgraduate School<br>University of Ulsan College of Medicine<br>Seoul, Korea                                |
| 2015. 6 – 2015. 7 | Visiting fellowship<br>Gastrointestinal oncology service<br>Memorial Sloan Kettering Cancer Center<br>New York City, New York, USA |

#### **Graduate Training**

- |                   |                                    |
|-------------------|------------------------------------|
| 2006. 3 – 2007. 2 | Internship<br>Asan Medical Center, |
|-------------------|------------------------------------|

University of Ulsan College of Medicine  
Seoul, Korea

2007. 3 – 2011. 2      Residency, Internal Medicine,  
Asan Medical Center,  
University of Ulsan College of Medicine  
Seoul, Korea
2011. 3 – 2012. 4      Medical Officer, Captain,  
1<sup>st</sup> artillery group, Republic of Korea Army,  
Korea
2012. 4 – 2014. 4      Medical Officer, Captain,  
Defense Security Command, Republic of Korea Army,  
Korea
2014. 5 – 2016. 2      Clinical fellow, Medical Oncology,  
Department of Oncology, Asan Medical Center,  
University of Ulsan College of Medicine, Seoul, Korea
2016. 3 –                Assistant Professor, Medical Oncology,  
Department of Oncology, Asan Medical Center,  
University of Ulsan College of Medicine, Seoul, Korea

## **Certification**

- 2011      Internal Medicine, Korean Board of Internal Medicine (#12657)
- 2014      Clinical Research Ethics (KGCP) (May 27, 2014, Korea Center for  
Control and Prevention)
- 2016      Clinical Research Ethics (KGCP) (April 12, 2016, Korea Center for  
Control and Prevention)

## **Licensure**

- 2006      Korean Medical License (#89633)

## **Affiliation**

- Member, Korean Medical Association  
Member, Korean Association of Internal Medicine  
Member, Korean Association of Clinical Oncology  
Member, Korean Cancer Association  
Member, American Society of Clinical Oncology  
Member, European Society of Medical Oncology

## **Publications in Journals:**

69. **Yoo C**, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. *Cancer Res Treat*. 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print]
68. Chae H, Cho H, **Yoo C\***, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. *Int J Biol Markers*. doi: 10.1177/1724600818777239. E-pub ahead. **\*Contributed as co-corresponding author**
67. Chae H, **Yoo C**, Yoon JA, Lee HJ, Kim KP, Kim JE, Ahn JH, Jung KH, Gong G, Kim SB. FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. *J Breast Cancer*. 2018 Mar;21(1):45-50. doi: 10.4048/jbc.2018.21.1.45. **\*Contributed as co-first author**
66. Kang J, Hwang I, **Yoo C**, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Hong SM, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. *Invest New Drugs*. 2018 Apr 3. doi: 10.1007/s10637-018-0598-5. **\*Contributed as co-corresponding author**
65. **Yoo C**, Han B, Kim HS, Kim KP, Kim D, Jeong JH, Lee JL, Kim TW et al., Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. *Cancer Res Treat*. 2018; Jan 8: Epub-ahead.
64. Ahn Y, Ahn HJ, Yoon DH, Hong JY, **Yoo C**, Kim S, Huh J, Suh C. Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. *Blood Res*. 2017;52(4):285-92.
63. Shin SJ, Park H, Sung YN, **Yoo C**, Hwang DW, Park JH, et al., Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. *Cancer Res Treat* 2017;Dec 20: Epub-ahead.
62. Cho H, **Yoo C**, Kim KP, Jeong JH, Kang J, Chang HM et al., Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. *Invest New Drugs* 2017;Dec 1, e-pub ahead. **\*Contributed as co-corresponding author**
61. Na YS, Ryu MH, **Yoo C**, Lee JK, Park JM, Lee CW, Lee SY, Shin YK, Ku JL, Ahn SM, Kang YK, Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors. *Oncotarget* 2017;8(44):76712-21.
60. Lee K, **Yoo C\***, Kim KP, Park KJ, Chang HM et al. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. *Invest New Drugs*. 2018;36(1):163-9. **\*Contributed as co-corresponding author**
59. Seo S, **Yoo C\***, Kim KP, Ryoo BY, Chang HM et al. Clinical Outcomes of Patients with Resectable Pancreatic Acinar Cell Carcinoma. *J Dig Dis* 2017 epub ahead. **\*Contributed as co-first author**
58. Kim BJ, Hyung J, **Yoo C\***, Kim KP, Park SJ, et al. Prognostic factors in patients with advanced



- biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. *Cancer Chemother Pharmacol.* 2017;80(1):209-15. **\*Contributed as co-corresponding author**
57. **Yoo C**, Kang J, Kim KP, Lee JL, Ryoo BY, et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. *Oncotarget* 2017;8(29):46337-47
56. **Yoo C**, Kang J, Kim D, Kim KP, Ryoo BY, et al. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. *Oncotarget* 2017;8(24):38592-691
55. Kim BJ, **Yoo C\***, Kim K-P, Hyung J, Park S-J, Ryoo B-Y, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. *Nature Publishing Group*; 2017 Jan 12;:1-7. **\*contributed as co-first author**
54. **Yoo C**, Cho H, Song MJ, Hong S-M, Kim K-P, Chang H-M, et al. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. *Cancer Chemother Pharmacol.* Springer Berlin Heidelberg; 2016 Dec 10;79(1):139-46.
53. Seo S, Hong JY, Yoon S, **Yoo C**, Park JH, Lee JB. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. *Oncotarget.* 2016.
52. **Yoo C**, Kim BJ, Kim K-P, Lee J-L, Kim TW, Ryoo B-Y, et al. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen. *Cancer Res Treat.* 2016 Nov 9;:1-7.
51. **Yoo C**, Ryu MH, Na YS, Ryoo BY, Lee CW, Kang YK. Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. *Br J Cancer* 2016;114:1185-90.
50. **Yoo C**, Ryu MH, Nam BH, Ryoo BY, Demetri GD, Kang YK. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). *Eur J Cancer.* 2016 Jan;52:201-8
49. Yoon S, **Yoo C\***, Ryu MH, Kang MJ, Ryoo BY, Park SR, Yook JH, Oh ST, Yoo MW, Kim BS, Kang YK. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer. *Gastric Cancer.* 2015 Dec 11. [Epub ahead of print] **\*contributed as co-first author**
48. **Yoo C**, Park YS. Companion diagnostics for the targeted therapy of gastric cancer. *World J Gastroenterol* 2015; 21(39):10948-10955
47. **Yoo C**, Kang YK. Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial. *Clinical Investigation* 2015; 5(7): 665-675
46. Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, **Yoo C**, et al. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase 3 trial (SOS). *Ann Oncol* 2015

Oct;26(10):2097-101.

45. **Yoo C**, Kim SB, Ro J, Im SA, Im YH, et al. Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. *Cancer Res Treat* 2016 Apr; 48(2):499-507.
44. **Yoo C**, Ryu MH, Jo J, Park I, Ryoo BY, Kang YK. Efficacy of Imatinib in Patients with Platelet-derived Growth Factor Receptor Alpha-mutated Gastrointestinal Stromal Tumors. *Cancer Res Treat* 2016 Apr; 48(2): 546-552
43. **Yoo C**, Yoon S, Lee DH, Park SI, Kim DK, et al. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection. *Clin Lung Cancer* 2015 E-pub ahead
42. **Yoo C**, Yoon DH, Kim S, Huh J, Park CS, et al. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. *Hematol Oncol* 2015 Epub-ahead
41. **Yoo C**, Koh YW, Park YS, Ryu M-H, Ryoo B-Y, et al. Prognostic relevance of p53 overexpression in gastrointestinal stromal tumors of the small intestine: potential implication for adjuvant treatment with imatinib. *Ann Surg Oncol* 2015 March. E-pub ahead
40. Ryu M-H, **Yoo C**,\* Kim JG, Ryoo B-Y, Park YS, Park SR, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. *European Journal of Cancer*. 2015 Mar;51:482-488 **\*contributed as co-first author**.
39. Park JH, Ryu M-H, Kim HJ, Ryoo B-Y, **Yoo C**, Park I, et al. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. *Gastric Cancer*. 2015 Jan 23. E-pub ahead
38. **Yoo C**, Ryu M-H, Park YS, Yoo M-W, Park SR, Ryoo B-Y, et al. Intraoperatively Assessed Macroscopic Serosal Changes in Patients with Curatively Resected Advanced Gastric Cancer: Clinical Implications for Prognosis and Peritoneal Recurrence. *Ann Surg Oncol*. 2015 Jan 21. E-pub ahead
37. Seo S, **Yoo C**, Yoon DH, Kim S, Park JS, Park C-S, et al. Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience. *Blood Res*. 2014 Dec;49(4):253-8.
36. **Yoo C**, Kim S-B, Ahn J-H, Kim JE, Jung KH, Gong G-Y, et al. A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. *Cancer Res Treat*. 2014 Nov 27. E-pub ahead
35. **Yoo C**, Ryu MH, Na YS, Ryoo BY, Park SR, Kang YK. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. *Annals of Oncology*. 2014 Nov;25(11):2272-7.
34. **Yoo C**, Yoon DH, Suh C. Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. *Blood Res*. 2014 Sep;49(3):148-53.
33. Kim S-B, **Yoo C**,\* Ro J, Im S-A, Im Y-H, Kim JH, et al. Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial. *Invest New Drugs*. 2014 Aug;32(4):753-61.

\*contributed as co-first author

32. **Yoo C**, Yoon DH, Yoon S, Kim S, Huh J, Park CJ, et al. Prognostic impact of  $\beta$  2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. *Leuk Lymphoma*. 2015 Mar;56(3):688-93.
31. **Yoo C**, Yoon DH, Jo J-C, Yoon S, Kim S, Lee B-J, et al. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. *Ann Hematol*. 2014 Jun;93(6):995-1000.
30. **Yoo C**, Ryu M-H, Na Y-S, Ryoo B-Y, Lee C-W, Maeng J, et al. Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. *Invest New Drugs*. 2014 Apr;32(2):271-8.
29. Kang Y-K, Yook JH, Chang H-M, Ryu M-H, **Yoo C**, Zang DY, et al. Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). *Cancer Chemother Pharmacol*. 2014 Jan;73(1):139-49.
28. **Yoo C**, Lee J, Rha SY, Park KH, Kim TM, Kim YJ, et al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. *Invest New Drugs*. 2013 Dec;31(6):1602-8.
27. Kang YK, **Yoo C**, Ryoo BY, Lee JJ, Tan E, Park I, et al. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. *Br J Cancer*. 2013 Oct 29;109(9):2309-15.
26. Kang Y-K, Ryu M-H, **Yoo C**, Ryoo B-Y, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncology*. Elsevier Ltd; 2013 Oct 17;14(12):1175-82.
25. **Yoo C**, Ryu M-H, Ryoo B-Y, Beck MY, Kang Y-K. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. *Invest New Drugs*. 2013 Oct;31(5):1367-74.
24. **Yoo C**, Yun MR, Ahn J-H, Jung KH, Kim HJ, Kim JE, et al. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. *Cancer Chemother Pharmacol*. 2013 Sep;72(3):565-75.
23. Yoon S, Ryu M-H, **Yoo C**, Beck MY, Ryoo B-Y, Kang Y-K. Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients. *J Korean Med Sci*. 2013 Aug;28(8):1248-52.
22. **Yoo C**, Yoon DH, Kim JE, Jo J, Park S-J, Yoon S-K, et al. Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma. *Int J Hematol*. 2013 Feb;97(2):232-9.
21. **Yoo C**, Park JH, Yoon DH, Park S-I, Kim HR, Kim JH, et al. Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. *The Annals of Thoracic Surgery*. 2012 Dec;94(6):1862-8.
20. **Yoo C**, Kang Y-K. An update of adjuvant treatments for localized advanced gastric cancer. *Clinical Investigation*. 2012 Nov;2(11):1101-8.
19. **Yoo C**, Ryu M-H, Ryoo B-Y, Beck MY, Chang H-M, Lee J-L, et al. Changes in imatinib plasma



- trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. *Invest New Drugs*. Springer US; 2012 Aug;30(4):1703–8.
18. **Yoo C**, Ahn J-H, Jung KH, Kim S-B, Kim H-H, Shin HJ, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. *J Breast Cancer*. 2012 Jun;15(2):203–10.
  17. Kang Y-K, **Yoo C**. Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions. *Am Soc Clin Oncol Educ Book*. 2012;:e31–4.
  16. Park S-K, Choi J-K, **Yoo C**, Park S-J, Lee T-H, Lee J-H, et al. Toxoplasma Encephalitis in an Allogeneic Hematopoietic Stem Cell Transplant Recipient in Korea. *Korean J Intern Med*. 2012;27(2):235.
  15. Kim K-P, Ryu M-H, **Yoo C**, Ryoo B-Y, Choi DR, Chang H-M, et al. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. *Cancer Chemother Pharmacol*. 2011 Aug;68(2):285–91.
  14. **Yoo C**, Lee DH, Kim JE, Jo J, Yoon DH, Sohn BS, et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. *Ann Hematol*. 2011 Jul;90(7):797–802.
  13. Kang Y-K, Ryu M-H, **Yoo C**, Chang H-M, Yook JH, Oh ST, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. *Cancer Chemother Pharmacol*. 2011 Jun;67(6):1435–43.
  12. **Yoo C**, Kim S-B, Ahn J-H, Jung KH, Ahn Y, Gong G, et al. Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report. *J Breast Cancer*. 2011 Jun;14(2):135–9.
  11. Kim JE, Lee DH, **Yoo C**, Kim S, Kim S-W, Lee J-S, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. *Leuk Res*. Elsevier Ltd; 2011 Feb;35(2):183–7.
  10. **Yoo C**, Kim JE, Lee J-L, Ahn J-H, Lee DH, Lee J-S, et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. *Jpn J Clin Oncol*. 2010 Oct;40(10):980–5.
  9. **Yoo C**, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, et al. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma. *Korean J Intern Med*. 2010 Sep;25(3):301–8.
  8. Kim J-E, **Yoo C**, Kim S, Lee DH, Kim S-W, Lee JS, et al. Optimal timing of G-CSF administration for effective autologous stem cell collection. *Bone Marrow Transplantation*. 2011 Jun;46(6):802–12.
  7. Kim JE, **Yoo C**, Lee DH, Kim S-W, Lee J-S, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. *Ann Hematol*. 2010 Apr;89(4):391–7.
  6. **Yoo C**, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, et al. Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib. *Journal of Clinical Oncology*. 2010 Mar

18;28(9):1554–9.

5. Park I, Lee J-L, Ryu M-H, Chang H-M, Kim TW, Sym S-J, et al. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. *Cancer Chemother Pharmacol.* 2010 Feb;65(3):473–80.
4. **Yoo C**, Hwang JY, Kim J-E, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. *Br J Cancer.* Nature Publishing Group; 2009 Oct 13;101(10):1658–63.
3. Na S, Choi KD, **Yoo C**, Chang Y, Song HJ, Lee G-H, et al. Verrucous carcinoma of the esophagus. *Gastrointest Endosc.* American Society for Gastrointestinal Endoscopy; 2009 Oct;70(4):803–6.
2. **Yoo C**, Kim JE, Yoon S-K, Kim SC, Ahn J-H, Kim TW, et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. *Sarcoma.* Hindawi Publishing Corporation; 2009;2009:360875.
1. **Yoo C**, Ryu M-H, Huh J, Park JH, Kang HJ, Ahn HS, et al. Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. *Am J Hematol.* 2007 Sep;82(9):821–3.

## **Honors and Achievements:**

10. Best presentation Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting 2018  
Efficacy and Safety of regorafenib after progression on sorafenib in practice of Korea in patients with advanced hepatocellular carcinoma
9. Blood Research Best Paper 2018 by Korean Hematology Society  
Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor
8. Korean Cancer Research Foundation Merit Award 2015  
Intraoperatively Assessed Macroscopic Serosal Changes in Patients with Curatively Resected Advanced Gastric Cancer: Clinical Implications for Prognosis and Peritoneal Recurrence
7. GlaxoSmithKline Award at the 16<sup>th</sup> Annual Meeting of Korean Cancer Association 2014  
Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST)
6. 2014 ASCO Conquer Cancer Foundation Merit Award  
Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST)
5. GlaxoSmithKline Award at the 15<sup>th</sup> Annual Meeting of Korean Cancer Association 2013  
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft tissue sarcomas after failure of anthracycline and ifosfamide
4. 2013 GI ASCO Merit Award, January 24-26, 2013, San Francisco, California  
Phase I Dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer
3. GlaxoSmithKline Award at the 10<sup>th</sup> International Conference of the Asian Clinical Oncology Society





## 2012

- Update of AMC 0101 trial: randomized phase III trial comparing Mf with iceMFP regimen in patients with serosa-positive gastric cancer after curative resection
2. Young Investigator's Award of 9<sup>th</sup> Asian Clinical Oncology Society 2010, Gifu, Japan  
Predictive factors for pathologic complete response following neoadjuvant chemotherapy in patients with breast cancer
  1. Merit award of Korean Association of Clinical Oncology Annual Meeting 2009  
A cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib

## **Abstracts presented at the international symposiums (Selected):**

10. Gastrointestinal Cancer Symposium 2015, January 15-18, 2015, San Francisco, California  
Intraoperatively Assessed Macroscopic Serosal Changes in Patients with Curatively Resected Advanced Gastric Cancer: Clinical Implications for Prognosis and Peritoneal Recurrence (poster presentation)
9. Annual Meeting of ASCO 2014, May 31-June 3, Chicago, IL  
Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST) (poster presentation)
8. Gastrointestinal Cancer Symposium 2013, January 24-26, 2013, San Francisco, California  
Phase I Dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer (poster presentation)
7. 2012 American Society of Clinical Oncology Annual Meeting, May 31-June 5, 2012, Chicago, IL USA (poster presentation)  
C Yoo, MH Ryu, BR Ryoo, MY Beck, I Park, YK Kang  
Imatinib pharmacokinetics at escalated dose in patients with advanced gastrointestinal stromal tumors
6. 9<sup>th</sup> International Conference of The Asian Clinical Oncology Society, August 24-27, Gifu-city, Gifu, Japan (oral presentation)  
C.Yoo, J-H Ahn, KH Jung, S-B Kim, H-H Kim, HJ Shin, S-H Ahn, G-Y Gong  
Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemotherapy in Patients with Breast Cancer
5. 2010 American Society of Clinical Oncology Annual Meeting, June 4-8, 2010, Chicago, IL, USA (poster discussion)  
C.Yoo, S-K Yoon, DH Lee, C.Suh, J-S LEE, S-I Park, D-K Kim, YH Kim, WS Kim, S-W Kim  
Prognostic Significance of the Number of Tumor (+) N2 Nodes in N2-Stage IIIA Non-Small Cell Lung Cancer After Curative Resection
4. 2009 American Society of Clinical Oncology Annual Meeting, May 29 – June 2, 2009, Orlando, Florida, USA (poster presentation)



C.Yoo, S Kim, BS Sohn, JE Kim, DH Yoon, J Huh, DH Lee, SW Kim, J-S Lee, C Suh: The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP

3. 2010 Gastrointestinal Cancers Symposium, January 22-24, 2010, Orlando, Florida, USA (poster presentation)

C Yoo, M-H Ryu, BW Kang, S-K Yoon, B-Y Ryoo, H-M Chang, J-L Lee, MY Beck, TW Kim, Y-K Kang: Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: Impact of gastrointestinal resection on exposure to imatinib

2. 2009 Annual Meeting of the American Society of Hematology, 2009, New Orleans, LA, USA (poster presentation)

C Yoo, JE Kim, BS Sohn, DH Yoon, S Kim, DH Lee, SW Kim, J-S Lee, C Suh: Prognostic impact of mid-treatment PET in patients with diffuse large B-cell lymphoma who achieved metabolic CR at post-treatment PET

1. 2005 European Clinical Cancer Organization 13<sup>th</sup> conference (oral presentation)

C Yoo, M-H Ryu, J Huh, JH Park, HJ Kang, HS Ahn, Y Lee, MJ Kim, H Lee, TW Kim, HM Chang, J-L Lee, Y-K Kang: Ocular adnexal lymphoma is highly associated with Chlamydia psittaci

## **Ongoing Research Support**

### **2016-728, 2017-728 Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea**

Changhoon Yoo (PI),

05/01/2016-12/31/2018

Development of research platform for biomarker analysis in multidisciplinary treatment of borderline resectable pancreatic cancer

Role: PI

### **NRF-2016M3A9E8941331, Ministry of Science, ICT and Future Planning, Korea**

Changhoon Yoo (PI)

11/01/2016-07/31/2020

Development of immune scoring and immune monitoring algorithm in patients with cholangiocarcinoma based on prospective trial

Role: PI

### **2017-752, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea**

Changhoon Yoo (PI)

01/02/2017-12/31/2018

Evaluation of immune microenvironment of cholangiocarcinoma

Role: PI

## **Clinical trials involved:**

No.	Study period	Disease	Phase	Sponsor	Role
1	2017/10/31~2019/10/31	Pancreatic cancer	II	SIT	PI



2	2017/10/01~2019/10/01	Pancreatic cancer	II	SIT	Sub-I
3	2017/06/01~2020/06/01	Biliary tract cancer	II	IIT	Sub-I
4	2017/05/06~2019/05/06	Neuroendocrine tumor	II	IIT	PI
5	2017/02/01~2018/05/01	Hepatocellular carcinoma	I/II	SIT	Sub-I
6	2016/07/01~2018/12/31	Hepatocellular carcinoma	II/III	SIT	Sub-I
7	2016/05/31~2018/12/31	Biliary tract cancer	II	SIT	Sub-I
8	2016/06/31~2017/12/31	Hepatocellular carcinoma/Pancreatic cancer	I	SIT	Sub-I
9	2016/05/31~2018/12/31	Pancreatic cancer	II	IIT	Sub-I
10	2015/05/31~2017/12/31	Hepatocellular carcinoma	I	SIT	Sub-I
11	2015/05/31~2017/12/31	Pancreatic cancer	III	SIT	Sub-I
12	2015/03/26~2018/06/15	Lymphoma	II	SIT	Sub-I
13	2014/11/18~2023/06/15	Multiple myeloma	III	SIT	Sub-I
14	2015/06/20~2022/02/28	Multiple myeloma	III	SIT	Sub-I
15	2014/07/07~2020/07/31	Lymphoma	I/III	SIT	Sub-I
16	2014/06/16~2020/09/29	Multiple myeloma	III	SIT	Sub-I
17	2013/10/07~2018/05/16	Multiple myeloma	III	SIT	Sub-I
18	2013/09/02~2022/08/06	Lymphoma	III	IIT	Sub-I
19	2014/06/02~2017/06/05	Gastric cancer	III	SIT	Sub-I
20	2014/07/05~2018/03/15	Gastric cancer	III	SIT	Sub-I
21	2010/7/20~2013/07/20	Gastrointestinal stromal tumors	III	IIT	Sub-I
22	2009/12/14~2014/12/16	Gastric cancer	I/II	IIT	Sub-I
23	2014/03/01~2016/01/01	Pancreatic cancer	III	SIT	Sub-I

# HBP SURGERY WEEK 2019

& The 50<sup>th</sup> Annual congress of the  
Korean Association of HBP Surgery

APRIL 5 - 6, 2019 GRAND HILTON SEOUL, KOREA  
[www.khbps.org](http://www.khbps.org)



	1				
24	2014/06/23~2017/09/2 3	Pancreatic cancer	III	SIT	Sub-I